Related Experiment Video
Updated: Jun 4, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Device therapy in patients with heart failure and advanced age: too much too late?
Raymond Cutro1, Michael W Rich, Paul J Hauptman
1Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
Insights
Implantable cardioverter-defibrillators (ICDs) offer limited benefit for most patients over 75, while cardiac resynchronization therapy (CRT) may improve quality of life in select elderly heart failure patients.
Area of Science:
- Cardiology
- Geriatrics
- Biomedical Engineering
Background:
- Increasing prevalence of implantable cardiac rhythm devices in aging populations.
- Limited data on the efficacy and safety of device therapy in patients over 75 years old.
Purpose of the Study:
- To review the evidence for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in elderly heart failure patients.
- To assess efficacy, complications, indications, cost, and controversies of device therapy in the geriatric population.
Main Methods:
- Systematic review of current evidence on ICDs and CRT in elderly heart failure patients.
- Analysis of major device trials, focusing on participants over 75 years of age.
Main Results:
- Implantable cardioverter-defibrillators (ICDs) show reduced net clinical benefit in most patients over 75 due to higher complication rates and costs.
- Cardiac resynchronization therapy (CRT) demonstrates improved quality of life in elderly patients at acceptable costs.
Conclusions:
- ICDs are unlikely to be favorable for most patients over 75-80 years.
- Cardiac resynchronization therapy (CRT) is a potentially attractive option for carefully selected elderly patients with heart failure.
Abstract:
Expanding indications for implantable cardiac rhythm devices coupled with the aging of the population have led to a progressive rise in the number of elderly patients referred for device implantation. However, the value of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in elderly patients remains unproven, in part because few patients over 75 years of age were enrolled in the major device trials. In this article, we summarize the current evidence base regarding the use of device therapy in elderly heart failure patients. We review the efficacy, complications, indications, cost, and current controversies surrounding the use of ICDs and CRT in the geriatric age group. We conclude that reduced benefit coupled with higher complication rates and associated higher costs make it unlikely that the net clinical benefit of an ICD is favorable in most patients over 75 to 80 years of age. Conversely, preliminary data indicate that elderly patients undergoing CRT experience improved quality of life at acceptable cost, suggesting that CRT may be an attractive therapeutic option in appropriately selected patients of advanced age.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Drug Dosing: Geriatric Patients